Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Ciliatech Raises €3.5M in Series A Funding
Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, […]
Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy
Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called […]
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon
I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, […]
Adcentrx Therapeutics Announces Completion of $38 million Series A+ Financing Led by Eight Roads Ventures
Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and […]
ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
ImmunoGen, a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of […]
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
OKYO Pharma, an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease […]
AmerisourceBergen Launches Cell and Gene Therapy Innovation Hub
AmerisourceBergen, a global healthcare company, has announced the launch of its Cell and Gene Therapy […]
Eplontersen Halted ATTRv-PN Disease Progression and Improved Neuropathy Impairment and Quality of Life in Study
Ionis Pharmaceuticals today announced that the Phase 3 NEURO-TTRansform study for AstraZeneca and Ionis’ eplontersen […]
Fractyl Health Announces the Initiation of a Global Registry Study of the Revita System™ in Patients With Inadequately Controlled Type 2 Diabetes (T2D)
Fractyl Health, a commercial-stage organ-editing metabolic therapeutics company focused on pioneering new approaches for the […]
Strand Therapeutics Appoints Colleen Wilson as Chief People Officer
Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, today […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more